Reported covered position: Chief of Staff, Rep. Robert Latta (2019-2022); Comms Dir, Rep. Robert Latta (2016-2019); Press Sec, Rep. Erik Paulsen (2014-2016); Press Sec, Rep. Jaime Herrera Beutler (2013-2014); Staff Asst, Rep. Jaime Herrera Beutler (2011-2013)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MICRO MEDICAL SOLUTIONS via INVARIANT LLC
2026 · third_quarter · Q3
Educate policymakers about new technologies for treating patients with advanced vascular disease.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Source: Senate LDA
| VSP |
| 11 |
| 2023–2026 |
| WATER AFFORDABILITY COALITION | 11 | 2024–2026 |
| BAXTER HEALTHCARE CORPORATION | 10 | 2023–2026 |
| CARRIER CORPORATION | 10 | 2022–2024 |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS | 10 | 2023–2025 |
| ACCENTURE LLP | 9 | 2023–2025 |
| APPLE INC. | 9 | 2023–2024 |
| MERCARI, INC. | 9 | 2022–2024 |
| ACCENTURE FEDERAL SERVICES LLC | 8 | 2023–2024 |
| GENERAL MATTER INC | 8 | 2024–2025 |
| 2U, LLC | 7 | 2025–2026 |
| Broadcom Inc. | 7 | 2022–2024 |
| CUMMINS INC. | 7 | 2023–2025 |
| OURARING INC. | 7 | 2025–2026 |
| PALANTIR TECHNOLOGIES, INC. | 7 | 2025–2026 |
| ZOCDOC | 7 | 2025–2026 |
| GEL BLASTER | 6 | 2022–2023 |
| GLYTEC, LLC | 6 | 2025–2026 |
| BARK TECHNOLOGIES, INC. | 5 | 2024–2025 |
| CLOAKED, INC. | 5 | 2024 |
| HEARST CORPORATION | 5 | 2025–2026 |
| KERECIS | 5 | 2025–2026 |
| PUDGY PENGUINS, INC. | 5 | 2025–2026 |
| ABRIDGE AI INC. | 4 | 2026 |
| ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) | 4 | 2025 |
| BAYOTECH | 4 | 2022–2023 |
| EGENESIS INC. | 4 | 2024–2025 |
| GUARDANT HEALTH, INC. | 4 | 2024–2025 |
| IMG ACADEMY FOUNDATION, INC. | 4 | 2025–2026 |
| INFINITA CITY INC. | 4 | 2026 |
| ROSWELL PARK COMPREHENSIVE CANCER CENTER | 4 | 2026 |
| SAGE | 4 | 2026 |
| TRAVELCENTERS OF AMERICA, INC. | 4 | 2022–2023 |
| BINTI, INC. | 3 | 2026 |
| CENTER FOR ORGAN RECOVERY & EDUCATION (LOBBYING ON BEHALF OF DONOR ALLIANCE) | 3 | 2026 |
| DSM-FIRMENICH | 3 | 2025–2026 |
| MICRO MEDICAL SOLUTIONS | 3 | 2026 |
| UDISENSE, INC. DBA NANIT | 3 | 2026 |
| WOUND PROS MANAGEMENT GROUP, INC. | 3 | 2025 |
| ANCOR | 2 | 2025 |
| FEDERATION OF AMERICAN HOSPITALS | 2 | 2023 |
| TRINET USA, INC. | 2 | 2026 |
| WONDERSCHOOL | 2 | 2026 |
| CERES, INC. | 1 | 2024 |
| GRAND PRAIRIE WATER COMMISSION | 1 | 2024 |
| NATIONAL VETERINARY ASSOCIATES | 1 | 2025 |
Monitor issues related to vision care plans, including H.R.1521 - DOC Access Act of 2025, and S.1716 - Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
To amend the Internal Revenue Code of 1986 to establish procedures relating to the attribution of errors in the case of third party payors of payroll taxes, and for other purposes.
Client: TRINET USA, INC. · Firm: INVARIANT LLC
Educate Members of Congress to clarify compliance regarding research and development tax credits and about H.R. 3223, to amend the Internal Revenue Code of 1986 to establish procedures relating to the attribution of errors in the case of third-party payors of payroll taxes, and for other purposes.
To amend the Internal Revenue Code of 1986 to establish procedures relating to the attribution of errors in the case of third party payors of payroll taxes, and for other purposes.
Client: TRINET USA, INC. · Firm: INVARIANT LLC
Educate Members of Congress to clarify compliance regarding research and development tax credits and about H.R. 3223, to amend the Internal Revenue Code of 1986 to establish procedures relating to the attribution of errors in the case of third-party payors of payroll taxes, and for other purposes.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.9260, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2027.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2026 (P.L.119-75).
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.9260, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2027.
Farm, Food, and National Security Act of 2026
Client: THE CAMPBELL'S COMPANY · Firm: INVARIANT LLC
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026.
Farm, Food, and National Security Act of 2026
Client: THE CAMPBELL'S COMPANY · Firm: INVARIANT LLC
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026.
Farm, Food, and National Security Act of 2026
Client: THE CAMPBELL'S COMPANY · Firm: INVARIANT LLC
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026 and S.5526, the Agricultural Act of 2026.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.9260, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2027.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.9260, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2027.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Monitor issues related to vision care plans, including H.R.1521 - DOC Access Act of 2025, and S.1716 - Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026 and S.5526, the Agricultural Act of 2026.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; monitor the TICKET Act (H.R. 1402/S. 430); monitor online privacy issues.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; monitor the TICKET Act (H.R. 1402/S. 430); monitor online privacy issues.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; monitor the TICKET Act (H.R. 1402/S. 430); monitor online privacy issues.
Accelerating Kids’ Access to Care Act of 2025
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
Accelerating Kids’ Access to Care Act of 2025
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
Accelerating Kids’ Access to Care Act of 2025
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including H.R.1521 DOC Access Act of 2025. Educate policymakers on the vision care market.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reintroduction of H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reintroduction of H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on the vision care market.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reintroduction of H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; monitor the TICKET Act (H.R. 1402/S. 430); monitor online privacy issues.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; monitor the TICKET Act (H.R. 1402/S. 430); monitor online privacy issues.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; monitor the TICKET Act (H.R. 1402/S. 430); monitor online privacy issues.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Making Insulin Affordable for All Children Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Drug Price Transparency in Medicaid Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Monitor improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530), Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26).
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests; discuss policies related to children's mental health, including in H.R.7808, EARLY Minds Act; monitor policy related to AI and privacy; discuss policies related to TRICARE.
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children's mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests. Monitor Emergency Medical Services for Kids Reauthorization.
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act and H.R.7808, Early Minds Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health; educate policymakers on Children's Hospitals Graduate Medical Education (CHGME); monitor issues related to lab-developed tests; monitor AI and health care technology privacy; monitor policies related to the 340B program.
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for childrens issues in S.2333, the Pandemic and All Hazards Preparedness Act; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
National Defense Authorization Act for Fiscal Year 2024
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
Pharmacy Benefits Manager Accountability Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Monitor improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530), Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26).
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Ensuring Access to Lifesaving Drugs Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Monitor efforts to enact legislation impacting the ticketing industry; educate policymakers regarding the companys ticketing policies and the consumer impacts of ticketing reform proposals; advocate passage of the Fans First Act (S.3457) and the House's TICKET Act (H.R.3950); monitor online privacy, including the American Privacy Rights Act discussion draft; advocate for improvements to the Kids Online Safety Act (S.1409); educate Members of Congress on the platform's content moderation policies and how content moderation proposals impact midsize online marketplaces.
Monitor efforts to enact legislation impacting the ticketing industry; monitor policies impacting the company's ticketing policies and the consumer impacts of ticketing reform proposals; support the Fans First Act (S.3457) and the TICKET Act (H.R.3950); monitor online privacy, including the American Privacy Rights Act discussion draft.
Monitor efforts to enact legislation impacting the ticketing industry; educate policymakers regarding the companys ticketing policies and the consumer impacts of ticketing reform proposals; advocate passage of the Fans First Act (S.3457) and the House's TICKET Act (H.R.3950); monitor online privacy, including the American Privacy Rights Act discussion draft; advocate for improvements to the Kids Online Safety Act (S.1409); educate Members of Congress on the platform's content moderation policies and how content moderation proposals impact midsize online marketplaces.
Monitor efforts to enact legislation impacting the ticketing industry; educate policymakers regarding the company's ticketing policies and the consumer impacts of ticketing reform proposals; advocate passage of the Fans First Act (S. 3457) and the House's TICKET Act (H.R. 3950); monitor online privacy, including the American Data Privacy and Protection Act; advocate for improvements to the Kids Online Safety Act (S. 1409); educate Members of Congress on the platform's content moderation policies and how content moderation proposals impact midsize online marketplaces.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement, including H.R.4758, Accelerating Kids Access to Care Act.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530), Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26).
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Advocate improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Monitor improvements to 1099-K reporting and withholding thresholds because of their impacts on live event organizers and creators, such as the Red Tape Reduction Act (S.1761), Cut Red Tape for Online Sales Act (H.R.3530, Saving Gig Economy Taxpayers Act (H.R.190), and Stop the Nosy Obsession with Online Payments (SNOOP) Act (H.R.488 and S.26)
Lowering Drug Costs for American Families Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Expanding Seniors' Access to Lower Cost Medicines Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on solutions to modernize child welfare systems through technology, with a focus on modularity, kinship care, and outcome-driven service delivery.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFINITA CITY INC. via INVARIANT LLC
2026 · third_quarter · Q3
Monitor policy issues related to high-fidelity Real-World Evidence to accelerate drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAGE via INVARIANT LLC
2026 · third_quarter · Q3
Monitor policies to support innovation in the senior living and long-term care sector. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABRIDGE AI INC. via INVARIANT LLC
2026 · third_quarter · Q3
Promote policies that enhance the role of AI-enabled clinical documentation technology in health care delivery.
Educate staff on the capabilities of AI-enabled scribe technology in health care settings.
Educate policymakers on the role of AI-enabled clinical documentation technology in health care delivery and in reducing clinician burnout.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
ROSWELL PARK COMPREHENSIVE CANCER CENTER via INVARIANT LLC
2026 · third_quarter · Q3
Educate policymakers about biomedical research, PPS-exempt cancer hospital payments, and strategies for cancer prevention and treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUDGY PENGUINS, INC. via INVARIANT LLC
2026 · third_quarter · Q3
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERICSSON INC. via INVARIANT LLC
2026 · third_quarter · Q3
Monitor artificial intelligence policy debate.
Outreach and monitor issues related to 5G technology and wireless network security.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRINET USA, INC. via INVARIANT LLC
2026 · third_quarter · Q3
Educate Members of Congress on professional employee organizations (PEOs); advocate for PEOs to continue to provide human resource benefits to small- and medium-sized businesses.
Educate Members of Congress to clarify compliance regarding research and development tax credits and about H.R. 3223, to amend the Internal Revenue Code of 1986 to establish procedures relating to the attribution of errors in the case of third-party payors of payroll taxes, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE BUSINESS ROUNDTABLE via INVARIANT LLC
2026 · third_quarter · Q3
Monitor tax policy.
Monitor data privacy issues; monitor consumer privacy proposals; monitor cybersecurity policy developments; monitor policy developments related to artificial intelligence.
Monitor immigration policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
UDISENSE, INC. DBA NANIT via INVARIANT LLC
2026 · third_quarter · Q3
Educate lawmakers about innovative infant and child health monitoring technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WONDERSCHOOL via INVARIANT LLC
2026 · third_quarter · Q3
Advancing policies that increase access, integrity, and affordability in the child care system.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2026 · third_quarter · Q3
Monitor issues affecting the medical device industry, including issues related to the supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2U, LLC via INVARIANT LLC
2026 · third_quarter · Q3
Discuss issues related to higher education and online learning.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Q3
Educate policymakers on the importance of effective glycemic management practices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, SENATE, Veterans Affairs, Dept of (VA)
DSM-FIRMENICH via INVARIANT LLC
2026 · third_quarter · Q3
Educate policymakers on the importance of biomanufacturing and protecting the domestic manufacturing capacity of vitamins.
Educate policymakers on the importance of UV filters in sunscreen and on issues related to women's health, maternal health, and infant formula supply.
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR), White House Office
THE CAMPBELL'S COMPANY via INVARIANT LLC
2026 · third_quarter · Q3
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026 and S.5526, the Agricultural Act of 2026.
Monitor and discuss proposals impacting the consumer packaged goods industry.
Filing targets: Agriculture, Dept of (USDA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
WATER COALITION AGAINST PFAS via INVARIANT LLC
2026 · third_quarter · Q3
Educate policymakers on passive receiver liability under P.L. 96-510, the Comprehensive Environmental Response, Compensation, and Liability Act of 1980. Advocate for support of H.R.1267, the Water Systems PFAS Liability Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OURARING INC. via INVARIANT LLC
2026 · third_quarter · Q3
Educate policymakers about innovative wearable technology and its role in preventive health.
Educate policymakers about protecting intellectual property rights.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2026 · third_quarter · Q3
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.9260, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR ORGAN RECOVERY & EDUCATION (LOBBYING ON BEHALF OF DONOR ALLIANCE) via INVARIANT LLC
2026 · third_quarter · Q3
Promote policies that enhance transparency and accessibility in the organ transplant process.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VSP via INVARIANT LLC
2026 · third_quarter · Q3
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2026 · third_quarter · Q3
Educate Members of Congress and the Administration about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; monitor issues related to the VA community care network.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CIGNA CORPORATION via INVARIANT LLC
2026 · third_quarter · Q3
Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance.
Monitor pharmacy issues related to TRICARE.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARST CORPORATION via INVARIANT LLC
2026 · third_quarter · Q3
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence-based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Monitor issues related to artificial intelligence.
Monitor electronic health record modernization efforts and educate policymakers on the role of independent care guidelines for veterans' health care.
SAGE via INVARIANT LLC
2026 · second_quarter · Q2
Monitor policies to support innovation in the senior living and long-term care sector. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2026 · second_quarter · Q2
Educate Members of Congress and the Administration about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; monitor issues related to the VA community care network.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICRO MEDICAL SOLUTIONS via INVARIANT LLC
2026 · second_quarter · Q2
Educate policymakers about new technologies for treating patients with advanced vascular disease.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Educate policymakers on solutions to modernize child welfare systems through technology, with a focus on modularity, kinship care, and outcome-driven service delivery.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFINITA CITY INC. via INVARIANT LLC
2026 · second_quarter · Q2
Monitor policy issues related to high-fidelity Real-World Evidence to accelerate drug development.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WONDERSCHOOL via INVARIANT LLC
2026 · second_quarter · Q2
Advancing policies that increase access, integrity, and affordability in the child care system.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ERICSSON INC. via INVARIANT LLC
2026 · second_quarter · Q2
Outreach and monitor issues related to 5G technology and wireless network security.
Monitor artificial intelligence policy debate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
THE CAMPBELL'S COMPANY via INVARIANT LLC
2026 · second_quarter · Q2
Monitor and discuss proposals impacting the consumer packaged goods industry.
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026.
Filing targets: Agriculture, Dept of (USDA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2026 · second_quarter · Q2
Monitor issues affecting the medical device industry, including issues related to the supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMG ACADEMY FOUNDATION, INC. via INVARIANT LLC
2026 · second_quarter · Q2
Educate policymakers about the importance of expanding collegiate athletic opportunities and adding more collegiate athletes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
VSP via INVARIANT LLC
2026 · second_quarter · Q2
Monitor issues related to vision care plans, including H.R.1521 - DOC Access Act of 2025, and S.1716 - Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2026 · second_quarter · Q2
Monitor pharmacy issues related to TRICARE.
Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; and proposals related to telehealth.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WATER COALITION AGAINST PFAS via INVARIANT LLC
2026 · second_quarter · Q2
Educate policymakers on passive receiver liability under P.L. 96-510, the Comprehensive Environmental Response, Compensation, and Liability Act of 1980. Advocate for support of H.R.1267, the Water Systems PFAS Liability Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSWELL PARK COMPREHENSIVE CANCER CENTER via INVARIANT LLC
2026 · second_quarter · Q2
Educate policymakers about biomedical research, PPS-exempt cancer hospital payments, and strategies for cancer prevention and treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2U, LLC via INVARIANT LLC
2026 · second_quarter · Q2
Discuss issues related to higher education and online learning.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OURARING INC. via INVARIANT LLC
2026 · second_quarter · Q2
Educate policymakers about protecting intellectual property rights.
Educate policymakers about innovative wearable technology and its role in preventive health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UDISENSE, INC. DBA NANIT via INVARIANT LLC
2026 · second_quarter · Q2
Educate lawmakers about innovative infant and child health monitoring technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR ORGAN RECOVERY & EDUCATION (LOBBYING ON BEHALF OF DONOR ALLIANCE) via INVARIANT LLC
2026 · second_quarter · Q2
Promote policies that enhance transparency and accessibility in the organ transplant process.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BUSINESS ROUNDTABLE via INVARIANT LLC
2026 · second_quarter · Q2
Monitor data privacy issues; monitor consumer privacy proposals; monitor cybersecurity policy developments; monitor policy developments related to artificial intelligence.
Monitor the immigration policy debate.
Monitor the tax policy debate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TRINET USA, INC. via INVARIANT LLC
2026 · second_quarter · Q2
Educate Members of Congress on professional employee organizations (PEOs); advocate for PEOs to continue to provide human resource benefits to small- and medium-sized businesses.
Educate Members of Congress to clarify compliance regarding research and development tax credits and about H.R. 3223, to amend the Internal Revenue Code of 1986 to establish procedures relating to the attribution of errors in the case of third-party payors of payroll taxes, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABRIDGE AI INC. via INVARIANT LLC
2026 · second_quarter · Q2
Promote policies that enhance the role of AI-enabled clinical documentation technology in health care delivery.
Educate policymakers on the role of AI-enabled clinical documentation technology in health care delivery and in reducing clinician burnout.
Educate staff on the capabilities of AI-enabled scribe technology in health care settings.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
PUDGY PENGUINS, INC. via INVARIANT LLC
2026 · second_quarter · Q2
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2026 · second_quarter · Q2
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.9260, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2027.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Q2
Educate policymakers on the importance of effective glycemic management practices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, SENATE, Veterans Affairs, Dept of (VA)
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2026 · second_quarter · Q2
Educate policymakers about security and data privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARST CORPORATION via INVARIANT LLC
2026 · second_quarter · Q2
Monitor electronic health record modernization efforts and educate policymakers on the role of independent care guidelines for veterans' health care.
Monitor issues related to artificial intelligence.
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence-based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
MICRO MEDICAL SOLUTIONS via INVARIANT LLC
2026 · second_quarter · RR
Educate policymakers about new technologies for treating patients with advanced vascular diseases.
2026 · second_quarter · RR
Modernize child welfare systems.
UDISENSE, INC. DBA NANIT via INVARIANT LLC
2026 · second_quarter · RR
Digital health technologies and infant monitoring devices.
KERECIS via INVARIANT LLC
2026 · first_quarter · Q1
Educate policymakers about advanced wound care technologies and patient access to skin substitutes for wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INFINITA CITY INC. via INVARIANT LLC
2026 · first_quarter · Q1
Monitor policy issues related to high-fidelity Real-World Evidence to accelerate drug development.
SAGE via INVARIANT LLC
2026 · first_quarter · Q1
Monitor policies to support innovation in the senior living and long-term care sector. Monitor issues related to the use of artificial intelligence in health care.
ABRIDGE AI INC. via INVARIANT LLC
2026 · first_quarter · Q1
Educate policymakers on the role of AI-enabled clinical documentation technology in health care delivery and in reducing clinician burnout.
Promote policies that enhance the role of AI-enabled clinical documentation technology in health care delivery.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
PUDGY PENGUINS, INC. via INVARIANT LLC
2026 · first_quarter · Q1
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2026 · first_quarter · Q1
Edcuate policymakers about security and data privacy.
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, and ASPR Supply Chain Control Tower.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2026 · first_quarter · Q1
Educate Members of Congress and the Administration about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; monitor issues related to the VA community care network.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE CAMPBELL'S COMPANY via INVARIANT LLC
2026 · first_quarter · Q1
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process, including H.R. 7567, the Farm, Food, and National Security Act of 2026.
Monitor and discuss proposals impacting the consumer packaged goods industry.
Filing targets: Agriculture, Dept of (USDA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
VSP via INVARIANT LLC
2026 · first_quarter · Q1
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OURARING INC. via INVARIANT LLC
2026 · first_quarter · Q1
Educate policymakers about protecting intellectual property rights.
Educate policymakers about innovative wearable technology and its role in preventive health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE BUSINESS ROUNDTABLE via INVARIANT LLC
2026 · first_quarter · Q1
Monitor data privacy issues; monitor consumer privacy proposals; monitor cybersecurity policy developments; monitor policy developments related to artificial intelligence.
Monitor the tax policy debate.
Monitor the immigration policy debate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROSWELL PARK COMPREHENSIVE CANCER CENTER via INVARIANT LLC
2026 · first_quarter · Q1
Educate policymakers about biomedical research, PPS-exempt cancer hospital payments, and strategies for cancer prevention and treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMG ACADEMY FOUNDATION, INC. via INVARIANT LLC
2026 · first_quarter · Q1
Educate policymakers about the importance of expanding collegiate athletic opportunities and adding more collegiate athletes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2U, LLC via INVARIANT LLC
2026 · first_quarter · Q1
Issues related to higher education and online learning.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2026 · first_quarter · Q1
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2026 (P.L.119-75).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
Educate policymakers on the importance of effective glycemic management practices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, SENATE, Veterans Affairs, Dept of (VA)
WATER COALITION AGAINST PFAS via INVARIANT LLC
2026 · first_quarter · Q1
Educate policy makers on passive receiver liability under P.L. 96-510, the Comprehensive Environmental Response, Compensation, and Liability Act of 1980. Advocate for support of H.R. 1267, the Water Systems PFAS Liability Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERICSSON INC. via INVARIANT LLC
2026 · first_quarter · Q1
Outreach and monitor issues related to 5G technology and wireless network security.
Monitor artificial intelligence policy debate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTER FOR ORGAN RECOVERY & EDUCATION (LOBBYING ON BEHALF OF DONOR ALLIANCE) via INVARIANT LLC
2026 · first_quarter · Q1
Promote policies that enhance transparency and accessibility in the organ transplant process.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2026 · first_quarter · Q1
Monitor issues affecting the medical device industry, including issues related to the supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2026 · first_quarter · Q1
Monitor pharmacy issues related to TRICARE.
Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; and proposals related to telehealth.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARST CORPORATION via INVARIANT LLC
2026 · first_quarter · Q1
Monitor issues related to artificial intelligence.
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence-based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Monitor electronic health record modernization efforts and educate policymakers on the role of independent care guidelines for veterans' health care.
INFINITA CITY INC. via INVARIANT LLC
2026 · first_quarter · RR
High-fidelity real-world evidence to accelerate drug development.
ABRIDGE AI INC. via INVARIANT LLC
2026 · first_quarter · RR
AI-enabled clinical documentation technologies in health care delivery.
AI-enabled clinical documentation technologies in health care delivery.
SAGE via INVARIANT LLC
2026 · first_quarter · RR
Innovation in the senior living and long-term care sector and the use of artificial intelligence in healthcare.
ROSWELL PARK COMPREHENSIVE CANCER CENTER via INVARIANT LLC
2026 · first_quarter · RR
Cancer research funding, Medicare reimbursement, and access to oncology care at the Department of Veterans Affairs.
Cancer research funding, Medicare reimbursement, and access to oncology care at the Department of Veterans Affairs.
Cancer research funding, Medicare reimbursement, and access to oncology care at the Department of Veterans Affairs.
KERECIS via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate policymakers about advanced wound care technologies and patient access to skin substitutes for wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CAMPBELL'S COMPANY via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate Members and staff about The Campbell's Company business and economic footprint; Monitor the Farm Bill reauthorization process.
Monitor and discuss proposals impacting the consumer packaged goods industry.
Filing targets: Agriculture, Dept of (USDA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
THE BUSINESS ROUNDTABLE via INVARIANT LLC
2025 · fourth_quarter · Q4
Monitor data privacy issues; monitor consumer privacy proposals; monitor cybersecurity policy developments; monitor policy developments related to artificial intelligence.
Monitor the tax policy debate.
Monitor the immigration policy debate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARST CORPORATION via INVARIANT LLC
2025 · fourth_quarter · Q4
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence-based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2025 · fourth_quarter · 4T
Educate policymakers about policies to support children's mental health care needs; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for children's issues in disaster preparedness efforts; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests.
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement. Support S.752/H.R. 1509, the Accelerating Kids Access to Care Act.
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) via INVARIANT LLC
2025 · fourth_quarter · Q4
Discuss issues related to the release of information industry and matters pertaining to patient health information, security, and interoperability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VSP via INVARIANT LLC
2025 · fourth_quarter · Q4
Monitor issues related to vision care plans, including H.R.1521, the DOC Access Act of 2025, and S.1716, the Vision Lab Choice Act of 2025. Educate policymakers on consumer choice and competition in the vision market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate Members of Congress and the Administration about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; monitor issues related to the VA community care network.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2025 · fourth_quarter · Q4
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, and ASPR Supply Chain Control Tower.
Edcuate policymakers about security and data privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; and proposals related to telehealth.
Monitor pharmacy issues related to TRICARE.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMG ACADEMY FOUNDATION, INC. via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate policymakers about the importance of expanding collegiate athletic opportunities and adding more collegiate athletes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2025 · fourth_quarter · Q4
Monitor issues affecting the medical device industry, including issues related to the supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PUDGY PENGUINS, INC. via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate Members of Congress on cryptocurrency issues and legislation, including P.L. 119-27, the GENIUS Act; H.R. 2392, the STABLE Act of 2025; and H.R. 3633, the CLARITY Act of 2025. Monitor cryptocurrency proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OURARING INC. via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate policymakers about innovative wearable technology and its role in preventive health.
Educate policymakers about protecting intellectual property rights.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2U, LLC via INVARIANT LLC
2025 · fourth_quarter · Q4
Issues related to higher education and online learning.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2025 · fourth_quarter · Q4
Advocate for H.R.4733, the Low-Income Household Water Assistance Program Establishment Act. Advocate for funding in H.R.5304/S.2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Educate policymakers on the importance of effective glycemic management practices.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, SENATE, Veterans Affairs, Dept of (VA)
WATER COALITION AGAINST PFAS via INVARIANT LLC
2025 · fourth_quarter · Q4
Educate policy makers on passive receiver liability under P.L. 96-510, the Comprehensive Environmental Response, Compensation, and Liability Act of 1980. Advocate for support of H.R. 1267, the Water Systems PFAS Liability Protection Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ERICSSON INC. via INVARIANT LLC
2025 · fourth_quarter · Q4
Outreach and monitoring of issues related to 5G technology and wireless network security.
Monitor artificial intelligence policy debate.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IMG ACADEMY FOUNDATION, INC. via INVARIANT LLC
2025 · fourth_quarter · RR
Expanding college athletic rosters.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Cancer research funding, Medicare reimbursement, and access to oncology care at the Department of Veterans Affairs.
Monitor the final rule on the Defense Health Agency's (DHA) TRICARE; Reimbursement of Ambulatory Surgery Centers and Outpatient Services Provided in Cancer and Children's Hospitals for military-connected children.
Monitor policy and funding changes for NIH and pediatric research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE